Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Dozens of lawmakers are urging U.S. health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Companies are selling personalized compounded drugs that combine weight loss and erectile dysfunction treatments, but is this ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to ...

Wegovy is FDA-approved for weight loss in people with a BMI of 30 or more or 27 or higher with at least one weight-related health condition. Some insurance plans do cover it, though coverage varies.

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...